Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ABIVAX SA (ABVX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$84.18-5.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ABVX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improvement in EPS losses | A supporting condition in ABIVAX SA's published investment case. The stated target is EPS loss improves to >= -$3.26. | Broken | EPS loss worsens beyond -$3.64 in FY27 | Diluted EPS: EUR -1.47 per share FY2026-Q2; GAAP. Published target: EPS loss improves to >= -$3.26. Annual target cannot be compared with a quarterly or TTM observation. Sep 21, 2026-1.47 EUR/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 21, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk Healthcare investment with limited evidence to classify its longer-term business profile. The thesis remains unresolved because recent financial history is not sufficient to assess whether the business is executing consistently.
The snapshot provides no valuation level or market-expectations estimate, so it does not show whether ABVX is cheap, fair, or expensive versus peers. No fragility gates fired, but that alone does not establish what expectations are already reflected.
Near term, the latest quarter miss and the industry's high miss rate make the next result an important execution check. The Healthcare sector backdrop has improved, but the evidence does not establish a clear multi-year fundamental trajectory for ABVX.
The near-term setup depends partly on whether sector bellwethers VRTX, REGN, and MRNA continue to report strong results and guidance, or begin to weaken. A further weakening in jobs data could also increase recession concerns and pressure cyclical names; the snapshot does not clarify ABVX's specific sensitivity.
Over the next one to three years, the thesis is insufficiently supported by company-specific financial history, while sector momentum offers a possible tailwind and the recent miss remains a risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The drug could gain regulatory approval and address unmet medical needs. |
| Under Pressure |
| NDA approval is denied or significantly delayed beyond next 4 quarters |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth from Obefazimod commercialization | A primary condition in ABIVAX SA's published investment case. The stated target is revenue >= $88 million. | Intact | revenue falls below $75 million in FY27 | Revenue: EUR 0 FY2026-Q2; GAAP. Published target: revenue >= $88 million. Annual target cannot be compared with a quarterly or TTM observation. Sep 21, 20260 EUR · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.02 → $-3.44 · observed estimates
$0.11B → $0.07B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.02 | $105,003,136 | 4 / 10 |
| 2026-07-25 | $-3.02 | $105,003,136 | 4 / 10 |
| 2026-07-26 | $-3.02 | $105,003,136 | 4 / 10 |
| 2026-07-27 | $-3.02 | $105,003,136 | 4 / 10 |
| 2026-07-28 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-07-29 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-07-30 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-07-31 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-01 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-02 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-03 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-04 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-05 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-06 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-07 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-08 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-09 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-10 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-11 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-12 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-13 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-14 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-15 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-16 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-17 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-18 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-19 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-20 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-21 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-22 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-23 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-24 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-25 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-26 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-27 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-28 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-29 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-30 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-08-31 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-01 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-02 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-03 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-04 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-05 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-06 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-07 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-08 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-09 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-10 | $-3.06 | $105,473,974 | 4 / 10 |
| 2026-09-11 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-12 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-13 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-14 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-15 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-16 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-17 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-18 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-19 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-20 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-21 | $-3.13 | $101,075,969 | 4 / 10 |
| 2026-09-22 | $-3.19 | $94,075,315 | 4 / 10 |
| 2026-09-23 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-24 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-25 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-26 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-27 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-28 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-29 | $-3.53 | $93,954,011 | 4 / 10 |
| 2026-09-30 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-01 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-02 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-03 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-04 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-05 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-06 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-07 | $-3.62 | $93,939,635 | 4 / 10 |
| 2026-10-08 | $-3.62 | $70,874,693 | 4 / 10 |
| 2026-10-09 | $-3.62 | $70,874,693 | 4 / 10 |
| 2026-10-10 | $-3.68 | $46,660,947 | 4 / 10 |
| 2026-10-11 | $-3.68 | $46,660,947 | 4 / 10 |
| 2026-10-12 | $-3.68 | $46,660,947 | 4 / 10 |
| 2026-10-13 | $-3.68 | $46,660,947 | 4 / 10 |
| 2026-10-14 | $-3.67 | $46,560,137 | 4 / 10 |
| 2026-10-15 | $-3.67 | $46,554,797 | 4 / 10 |
| 2026-10-16 | $-3.67 | $46,554,797 | 4 / 10 |
| 2026-10-17 | $-3.67 | $46,554,797 | 4 / 10 |
| 2026-10-18 | $-3.67 | $46,554,797 | 4 / 10 |
| 2026-10-19 | $-3.67 | $46,554,797 | 4 / 10 |
| 2026-10-20 | $-3.58 | $46,554,797 | 4 / 10 |
| 2026-10-21 | $-3.44 | $46,449,915 | 4 / 10 |
| 2026-10-22 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-23 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-24 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-25 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-26 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-27 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-28 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-29 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-30 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-10-31 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-11-01 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-11-02 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-11-03 | $-3.44 | $74,064,732 | 4 / 10 |
| 2026-11-04 | $-3.44 | $74,064,732 | 4 / 10 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.